 |
 |
|
|
RESÚMENES DICIEMBRE 2006 |
Psychotic Disorders
& Antipsychotics
(Haga un click en la información del journal para acceder al resúmen)
Long-term safety and tolerability of
long-acting injectable risperidone
in patients with schizophrenia or schizoaffective disorder
Jean-Pierre Lindenmayer, Akbar Khan, Mariëlle
Eerdekens, Ilse Van Hove
and Stuart Kushner
European Neuropsychopharmacology. Volume
17, Issue 2, 15 January
2007, Pages 138-144
The effects
of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity
in schizophrenic patients:
A double blind study
Jakovljevic M, Pivac N, Mihaljevic-Peles A, Mustapic M, Relja M, Ljubicic D, Marcinko D, Muck-Seler D
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Nov 24; [Epub ahead of
print]
A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia
experiencing an acute exacerbation requiring hospitalization
Potkin SG,
Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C,
Rupnow MF, Bossie CA, Davidson M, Burtea V, Zhu Y, Trivedi JK
Schizophr Res. 2006 Jul;85(1-3):254-65
The effects
of olanzapine and fluphenazine on plasma cortisol, prolactin and muscle rigidity
in schizophrenic patients:
A double blind study
M. Jakovljevic, N. Pivac, A. Mihaljevic-Peles, M. Mustapic, M.
Relja, D. Ljubicic, D. Marcinko and D. Muck-Seler
Progress in Neuro-Psychopharmacology and Biological
Psychiatry. Article in Press
A 10-year retrospective study of inpatient
adolescents with schizophrenia/schizoaffective disorder and substance use
Gal Shoval, Gil Zalsman, Alan Apter, Robyne Diller,
Leo Sher and Abraham Weizman
Comprehensive Psychiatry. Volume 48, Issue 1, January-February 2007, Pages 1-7
No words for feelings: alexithymia
in schizophrenia patients and first-degree relatives
Mascha van 't Wout, André Aleman, Bob Bermond and René S. Kahn
Comprehensive Psychiatry. Volume 48, Issue 1, January-February 2007, Pages 27-33
Effectiveness of
Switching Antipsychotic Medications
Susan M. Essock, Nancy H. Covell,
Sonia M. Davis, T. Scott Stroup, Robert A. Rosenheck,
and Jeffrey A. Lieberman
Am J
Psychiatry 163:2090-2095, December 2006
Randomized
Comparison of Olanzapine Versus
Risperidone for the Treatment of First-Episode
Schizophrenia: 4-Month Outcomes
Delbert G. Robinson, Margaret G. Woerner,
Barbara Napolitano, Raman C. Patel, Serge M. Sevy,
Handan Gunduz-Bruce, Jose M. Soto-Perello,
Alan Mendelowitz, Ali Khadivi,
Rachel Miller, Joanne McCormack, Beth S. Lorell,
Martin L. Lesser, Nina R. Schooler, and John M. Kane
Am J
Psychiatry 163:2096-2102, December 2006
Impact of Modafinil on Prefrontal Executive Function in Schizophrenia
Michael D. Hunter, Venkatasubramanian Ganesan, Iain D. Wilkinson, and Sean A. Spence
Am J
Psychiatry 163:2184-2186, December 2006
Serum Free Fatty Acids and Glucose
Metabolism, Insulin Resistance in Schizophrenia with Chronic Antipsychotics
Cong-jie Wang, Zhi-jun Zhang, Jing Sun, Xiao-bing Zhang,
Xiao-dong Mou, Xiang-rong
Zhang, Xiao-fang Shang and Tai-quan Zhang
Biological Psychiatry. Volume
60, Issue 12, 15 December 2006, Pages 1309-1313
Relative risk of glucose
elevation during antipsychotic exposure in a Veterans Administration population
Duncan,
Erica; Dunlop, Boadie W; Boshoven,
William; Woolson, Sandra L; Hamer,
Robert M; Phillips, Lawrence
International
Clinical Psychopharmacology. 22(1):1-11, January 2007
Pharmacological treatment of
severe dyslipidaemia in patients with schizophrenia
Hanssens,
Linda; De Hert, Marc; Kalnicka,
Dita; van Winkel, Ruud; Wampers, Martien; Van Eyck, Dominique; Scheen,
Andre; Peuskens, Joseph
International
Clinical Psychopharmacology. 22(1):43-49, January 2007
Predictors of risk for relapse in patients
with schizophrenia or schizoaffective disorder during olanzapine
drug therapy
I. Lipkovich, W. Deberdt,
J.G. Csernansky, P. Buckley, J. Peuskens,
S. Kollack-Walker, Y. Zhang, H. Liu-Seifert
and J.P. Houston
Journal of Psychiatric Research. Volume 41, Issues 3-4, April-June 2007, Pages 305-310
A double-blind randomised
comparative trial of amisulpride versus olanzapine for 2 months
in the treatment of subjects with schizophrenia and comorbid depression
J.-M. Vanelle and S. Douki
European Psychiatry. Volume 21, Issue 8, December 2006, Pages 523-530
A naturalistic multicenter
study of intramuscular olanzapine
in the treatment of acutely agitated manic or schizophrenic
patients
L. San, B. Arranz, I. Querejeta, S. Barrio, J.
De la Gándara and V. Pérez
European Psychiatry. Volume 21, Issue 8, December 2006, Pages 539-543
The effect of atypical versus typical antipsychotics on tardive dyskinesia :
A naturalistic study
de Leon J
Eur Arch Psychiatry Clin Neurosci. 2006 Dec 5; [Epub ahead of print]
Obstetric complications and neurological abnormalities in neuroleptic-naive psychotic patients
Victor Peralta,
Manuel J. Cuesta and
Jose F. Serrano
Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and
Schizoaffective Disorder
Marc De Hert, Dita Kalnicka, Ruud van Winkel, Martien Wampers, Linda Hanssens, Dominique Van Eyck, Andre Scheen,
and Joseph Peuskens
J Clin Psychiatry 2006;67:1889-1896
A Double-Blind
Study of Combination of Clozapine With
Risperidone in Patients With Schizophrenia: Effects
on Cognition
Berna Binnur
Kıvırcık Akdede,
A. Elif Anıl Yağcıoğlu, Köksal Alptekin, Tolga I. Turgut, Mevhibe Tümüklü, M. Kâzım Yazıcı, Karu Jayathilake, Zeliha Tunca, Ahmet Göğüs¸,
and Herbert Y. Meltzer
J Clin Psychiatry 2006;67:1912-1919
Incidence of Tardive Dyskinesia and Tardive Dystonia in African
Peter N. van Harten,
Hans W. Hoek, Glenn E. Matroos, and Jim van Os
J Clin Psychiatry
2006;67:1920-1927
Relapse Rates in
Patients With Schizophrenia Receiving Aripiprazole in Comparison With Other Atypical Antipsychotics
Karen E. Moeller, Theresa I. Shireman, and Barry I. Liskow
J Clin Psychiatry 2006;67:1942-1947
Attitudes of
Psychiatrists Toward Antipsychotic Depot Medication
Stephan Heres,
Johannes Hamann, Werner Kissling,
and Stefan Leucht
J Clin Psychiatry 2006;67:1948-1953
White matter abnormalities and brain
activation in schizophrenia: A combined DTI and fMRI
study
Ralf G.M. Schlösser, Igor Nenadic, Gerd Wagner, Daniel Güllmar, Katrin von Consbruch, Sabine Köhler, C. Christoph Schultz,
Kathrin Koch, Clemens Fitzek, Paul M. Matthews, Jürgen R. Reichenbach and
Heinrich Sauer
Schizophrenia Research. Volume 89, Issues 1-3, January 2007, Pages 1-11
Cerebral grey, white matter and csf in never-medicated,
first-episode schizophrenia
Siew E.
Chua, Charlton Cheung, Vinci Cheung, Jack T.K. Tsang, Eric Y.H. Chen, Jason
C.H. Wong, Jason P.Y. Cheung, Lawrance Yip, Kin-shing Tai, John Suckling and Gráinne
M. McAlonan
Schizophrenia Research. Volume 89, Issues 1-3, January 2007, Pages 12-21
Parietal lobe volume
deficits in schizophrenia spectrum disorders
Shi-Yu Zhou, Michio Suzuki, Tsutomu Takahashi, Hirofumi Hagino, Yasuhiro
Kawasaki, Mie Matsui, Hikaru Seto and Masayoshi Kurachi
Schizophrenia Research. Volume 89, Issues 1-3, January 2007, Pages 35-48
MRI abnormalities of the hippocampus and cavum septi pellucidi
in females with schizotypal personality disorder
Chandlee C.
Dickey, Robert W. McCarley, Mina L. Xu, Larry J. Seidman, Martina M. Voglmaier, Margaret A. Niznikiewicz,
Erin Connor and Martha E. Shenton
Schizophrenia Research. Volume 89, Issues 1-3, January 2007, Pages 49-58
Structural analysis of the basal ganglia in
schizophrenia
Daniel Mamah, Lei Wang, Deanna Barch,
Gabriel A. de Erausquin, Mokhtar
Gado and John G. Csernansky
Schizophrenia Research. Volume 89, Issues 1-3, January 2007, Pages 59-71
Minor physical anomalies in schizophrenia: A
meta-analysis
Seth M. Weinberg,
Elizabeth A. Jenkins, Mary L. Marazita and Brion S. Maher
Schizophrenia Research. Volume 89, Issues 1-3, January 2007, Pages 72-85
Does antipsychotic polypharmacy
increase the risk for metabolic syndrome?
Schizophrenia Research. Volume 89, Issues 1-3, January 2007, Pages 91-100
Remission in early psychosis: Rates,
predictors, and clinical and functional outcome correlates
Robin Emsley, Jonathan Rabinowitz, Rossella Medori and Early
Psychosis Global Working Group
Schizophrenia Research. Volume 89, Issues 1-3, January 2007, Pages 129-139
A meta-analysis of cognitive change with
haloperidol in clinical trials of atypical antipsychotics:
Dose effects and comparison to practice effects
Neil D. Woodward,
Scot E. Purdon, Herbert Y. Meltzer and David H. Zald
Schizophrenia Research. Volume 89, Issues 1-3, January 2007, Pages 211-224
Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole
in psychiatric patients
Molden E, Lunde H, Lunder N, Refsum H
Ther Drug Monit. 2006 Dec;28(6):744-9
Negative symptoms of schizophrenia: a problem that will not go away
Stahl SM, Buckley
PF
Acta Psychiatrica
Scandinavica.
Volume 115
Issue 1 Page 4 - January 2007
Environment and
Schizophrenia: Environmental Factors in Schizophrenia: Childhood Trauma—A
Critical Review
Craig Morgan and Helen Fisher
Schizophrenia
Bulletin 2007 33(1):3-10
Deconstructing
Schizophrenia: An Overview of the Use of Endophenotypes
in Order to Understand a Complex Disorder
David L. Braff, Robert Freedman, Nicholas J. Schork and Irving I. Gottesman
Schizophrenia
Bulletin 2007 33(1):21-32
Neurophysiological
Endophenotypes of Schizophrenia: The Viability of
Selected Candidate Measures
Bruce I. Turetsky, Monica E. Calkins, Gregory
A. Light, Ann Olincy, Allen D. Radant
and Neal R. Swerdlow
Schizophrenia
Bulletin 2007 33(1):69-94
DSM and the Death
of Phenomenology in
Nancy C. Andreasen
Schizophrenia
Bulletin 2007 33(1):108-112
Is the
Stefan Leucht, Rolf R. Engel, Josef Bäuml and John M. Davis
Schizophrenia
Bulletin 2007 33(1):183-191
Brain
morphological changes associated with exposure to HSV1 in first-episode
schizophrenia
K M R Prasad, B
H Shirts, R H Yolken, M
Molecular Psychiatry (2007) 12, 105–113
Schizophrenia: more evidence for less glutamate
Paul D Morrison and Lyn S Pilowsky
Expert Review of Neurotherapeutics. January 2007, Vol. 7, No. 1, Pages 29-31
Relationship between estrogen
and schizophrenia
A M Mortimer
Expert Review of Neurotherapeutics. January 2007, Vol. 7, No. 1, Pages 45-55
Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian
patients switching from conventional antipsychotics
Zheng Lu, Jian Hu, Chih-Ken
Chen, Tsuo-Hung Lan,
Gregorio L. Diokno, Jr., Byoung
Yong Lee, Heather McElroy, Gavan Harrison and Qiuqing
Ang
Amisulpride-induced hyperprolactinemia
is reversible following discontinuation
Thomas Paparrigopoulos, John Liappas,
Elias Tzavellas, Iraklis Mourikis and Constantin Soldatos